Combination therapy with an anti - cd19 antibody and a purine analog

• 收藏
• 分享

专利权人:

MORPHOSYS AG

发明人:

ROJKJAER LISA,WINDERLICH MARK,AMERSDORFFER JUTTA,STEIDL STEFAN,KROHN SUSANNE

申请号：

NZ61777112

公开号：

NZ617771A

申请日:

2012.08.14

申请国别(地区):

NZ

年份:

2016

代理人:

摘要：

Disclosed is the use of a synergistic combination of: an antibody specific for CD19 and fludarabine, for the manufacture of a medicament for the treatment of non-Hodgkin&rsquos lymphoma, chronic lymphocytic leukaemia and/or acute lymphoblastic leukaemia, wherein the antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/